Literature DB >> 17612671

Antiarrhythmic drugs, patients, and the pharmaceutical industry: value for patients, physicians, pharmacists or shareholders?

A A M Wilde1, P Langendijk.   

Abstract

Entities:  

Year:  2007        PMID： 17612671      PMCID： PMC1847765          DOI： 10.1007/bf03085967

Source DB:  PubMed          Journal:  Neth Heart J        ISSN： 1568-5888            Impact factor:   2.380


× No keyword cloud information.
  6 in total

1.  The circadian pattern of the development of ventricular fibrillation in patients with Brugada syndrome.

Authors:  K Matsuo; T Kurita; M Inagaki; M Kakishita; N Aihara; W Shimizu; A Taguchi; K Suyama; S Kamakura; K Shimomura
Journal:  Eur Heart J       Date:  1999-03       Impact factor: 29.983

2.  Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators.

Authors: 
Journal:  Lancet       Date:  1997-11-15       Impact factor: 79.321

3.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1989-08-10       Impact factor: 91.245

4.  Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator.

Authors:  Paul Dorian; Martin Borggrefe; Hussein R Al-Khalidi; Stefan H Hohnloser; Jose M Brum; Daljit S Tatla; Johannes Brachmann; Robert J Myerburg; David S Cannom; Michael van der Laan; Michael J Holroyde; Igor Singer; Craig M Pratt
Journal:  Circulation       Date:  2004-11-08       Impact factor: 29.690

Review 5.  Efficacy of quinidine in high-risk patients with Brugada syndrome.

Authors:  Bernard Belhassen; Aharon Glick; Sami Viskin
Journal:  Circulation       Date:  2004-09-20       Impact factor: 29.690

6.  Electrical storms in Brugada syndrome successfully treated with isoproterenol infusion and quinidine orally.

Authors:  J K Jongman; N Jepkes-Bruin; A R Ramdat Misier; W P Beukema; P P H M Delnoy; H Oude Lutttikhuis; J H E Dambrink; J C A Hoorntje; A Elvan
Journal:  Neth Heart J       Date:  2007       Impact factor: 2.380
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.